about
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance.HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.Imaging appearance of granulomatous disease after intravesical Bacille Calmette-Guerin (BCG) treatment of bladder carcinomaA phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
P50
description
researcher ORCID ID = 0000-0002-0166-316X
@en
wetenschapper
@nl
name
Weining Ma
@ast
Weining Ma
@en
Weining Ma
@nl
type
label
Weining Ma
@ast
Weining Ma
@en
Weining Ma
@nl
prefLabel
Weining Ma
@ast
Weining Ma
@en
Weining Ma
@nl
P106
P31
P496
0000-0002-0166-316X